Did you get a chance to watch the educational symposium on nodular calcium at TCT 2022? If you missed it, we’ve got you covered!
Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Did you get a chance to watch the educational symposium on nodular calcium at TCT 2022? If you missed it, we’ve got you covered!
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, Treating Different Ca++ Morphologies, Female vs. Male Outcomes
Dr. Jaikirshan J. Khatri, MD, FACC, FSCAI Director of Complex Coronary Intervention Heart, Vascular & Thoracic Institute, at Cleveland Clinic; Cleveland, Ohio shares his calcium modification approach with Coronary IVL including his best practices for pulse management as well as how calcium is affected by the fractures caused by coronary IVL.
Topics: Coronary IVL, Shockwave C2, Calcium Corner
Despite often being more challenging to treat, female PCI patients are under-represented in published data, with no dedicated prospective studies performed on this population. To address this unmet need, Shockwave is launching EMPOWER CAD, the first prospective, female-only study of coronary interventions.
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, Treating Different Ca++ Morphologies, Female vs. Male Outcomes
Attending TCT in Boston in a few weeks? Want to get "wicked smart" about treating coronary calcium? Shockwave has a lot in store for you:
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
Dr. Suzanne J. Baron of Lahey Hospital and Medical Center, Burlington, Massachusetts talks about gender disparities of PCI outcomes in calcified lesions, citing the recent SCAI Expert Consensus Statement, which brings to light the under-representation of women in cardiovascular clinical trials. Dr. Baron also talks about the impact of IVL to improve outcomes in women with calcified disease based on the recently published sex specific analysis of Disrupt CAD Pooled data at SCAI 2022.
For more information on Coronary IVL CAD Pooled Gender Analysis data, please visit ItsTimeForAnIntervention.com
Topics: Coronary IVL, Shockwave C2, Calcium Corner
Dr. Stephan Heo of the New England Heart and Vascular Institute, Catholic Medical Center, Manchester, New Hampshire shares his decision-making process in approaching calcified lesions in complex PCI as well as strategies to deliver IVL with different GEC techniques when facing challenging vessel anatomy and calcium morphology.
Topics: Coronary IVL, Shockwave C2, Calcium Corner
At Shockwave, we are committed to doing everything we can to narrow the PCI gender inequality gap starting with clinical evidence presented at SCAI 2022 where Coronary IVL demonstrated sustained long term clinical outcomes and excellent safety in both women and men suggesting first line use of Coronary IVL for plaque modification in female patients with calcified lesions.
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Female vs. Male Outcomes
Leading female interventionalists came together at SCAI 2022 to discuss what they are most excited about in the interventional space today, share key takeaways from SCAI, and discuss the female focused initiatives that will help bridge the PCI gap in gender disparities going forward. From the JSCAI expert consensus, gender focused clinical evidence highlights at SCAI, and future research to SCAI WIN initiatives, these female leaders covered it all.
Listen to the podcast with Dr. Dawn Abbott, MD, Rhode Island Hospital, Dr. Suzanne Baron, MD, Lahey Hospital and Medical Center, Dr. Alexandra Lansky, MD, Yale University School of Medicine, Yale University and Dr. Nadia Sutton, MD, University of Michigan.
We hope you enjoy the episode and for more information on coronary IVL in women, please visit TimeForAnIntervention.com.
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, ChalkTalk Podcast, Female vs. Male Outcomes
In episode #9 of the ChalkTalk podcast, we speak with Alexandra Lansky, MD, FACC, FAHA, FSCAI, FESC, Professor of Medicine in Cardiology, and Director of Yale Cardiovascular Clinical Research Program at Yale University School of Medicine in New Haven, Connecticut, about her recent gender analyses at TCT21 and SCAI22, in which she presented the respective 30-day and 1-year outcomes broken out by women vs men that were enrolled in the Disrupt CAD clinical program.
Dr. Lansky shares the genesis of the analysis - previous research showing that female atherectomy patients have an increased risk for angiographic complications than their male counterparts,[i] and sheds light on what makes coronary IVL unique from a safety perspective. She concludes by discussing the recent publication of SCAI’s “Expert Consensus Statement on Sex-Specific Consideration in Myocardial Revascularization” in JSCAI, which referenced the role of IVL in female patients. The SCAI guidelines concluded, “while additional evidence is needed, these results taken in the context of outcomes with atherectomy devices suggest that IVL may emerge as a first-line therapy for plaque modification of calcified lesions in women specifically.”
We hope you enjoy the episode and for more information on coronary IVL in women, please visit TimeForAnIntervention.com.
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, ChalkTalk Podcast, Female vs. Male Outcomes
In a few weeks, we are headed to a city known for its sunshine and southern hospitality, Atlanta, Georgia, where SCAI 2022 is taking place this year. At the conference, leading calcium experts will share the 1-year results from the Randomized Disrupt PAD III Trial and 1-year sex specific outcomes with Coronary IVL.
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Peripheral Conferences, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, Shockwave M5 & Shockwave M5+
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
